# Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

> **NCT05430958** · PHASE1 · WITHDRAWN · sponsor: **Inovio Pharmaceuticals**

## Conditions studied

- Coronavirus Infection

## Interventions

- **DRUG:** INO-4800
- **DRUG:** INO-9112
- **DEVICE:** CELLECTRA® 2000

## Key facts

- **NCT ID:** NCT05430958
- **Lead sponsor:** Inovio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10
- **Primary completion:** 2024-03
- **Final completion:** 2024-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was withdrawn due to sponsor decision.
- **Last updated:** 2022-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430958, "Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05430958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*